US3616244A - Production of lincomycin sulfoxide - Google Patents
Production of lincomycin sulfoxide Download PDFInfo
- Publication number
- US3616244A US3616244A US769395A US3616244DA US3616244A US 3616244 A US3616244 A US 3616244A US 769395 A US769395 A US 769395A US 3616244D A US3616244D A US 3616244DA US 3616244 A US3616244 A US 3616244A
- Authority
- US
- United States
- Prior art keywords
- lincomycin
- sulfoxide
- methyl
- chloro
- deoxylincomycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XYBYQSDXLDETKO-UHFFFAOYSA-N N-[2-hydroxy-1-(3,4,5-trihydroxy-6-methylsulfinyloxan-2-yl)propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide Chemical compound CCCC1CC(N(C)C1)C(=O)NC(C(C)O)C2OC(C(O)C(O)C2O)S(=O)C XYBYQSDXLDETKO-UHFFFAOYSA-N 0.000 title claims description 20
- 238000004519 manufacturing process Methods 0.000 title description 5
- -1 lincomycin sulfoxides Chemical class 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 19
- 238000006213 oxygenation reaction Methods 0.000 claims abstract description 9
- 238000000855 fermentation Methods 0.000 claims description 19
- 230000004151 fermentation Effects 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 9
- 230000001706 oxygenating effect Effects 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 6
- 241000187399 Streptomyces lincolnensis Species 0.000 claims description 5
- 241000811277 Streptomyces armentosus Species 0.000 claims description 3
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims description 2
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims description 2
- 238000010564 aerobic fermentation Methods 0.000 claims 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 abstract description 26
- 229960005287 lincomycin Drugs 0.000 abstract description 21
- 239000003242 anti bacterial agent Substances 0.000 abstract description 4
- 230000002906 microbiologic effect Effects 0.000 abstract description 4
- 239000002609 medium Substances 0.000 description 24
- 239000002253 acid Substances 0.000 description 19
- 244000005700 microbiome Species 0.000 description 17
- 235000013405 beer Nutrition 0.000 description 16
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 241000228245 Aspergillus niger Species 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 150000003462 sulfoxides Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- YTPMCWYIRHLEGM-BQYQJAHWSA-N 1-[(e)-2-propylsulfonylethenyl]sulfonylpropane Chemical compound CCCS(=O)(=O)\C=C\S(=O)(=O)CCC YTPMCWYIRHLEGM-BQYQJAHWSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 241000970875 Streptomyces spectabilis Species 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 102000007544 Whey Proteins Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000010699 lard oil Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013379 molasses Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 101150089644 Rnls gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 235000006085 Vigna mungo var mungo Nutrition 0.000 description 1
- 240000005616 Vigna mungo var. mungo Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- NGPGDYLVALNKEG-UHFFFAOYSA-N azanium;azane;2,3,4-trihydroxy-4-oxobutanoate Chemical compound [NH4+].[NH4+].[O-]C(=O)C(O)C(O)C([O-])=O NGPGDYLVALNKEG-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical group ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- PWATWSYOIIXYMA-UHFFFAOYSA-N n-pentylbenzene Natural products CCCCCC1=CC=CC=C1 PWATWSYOIIXYMA-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009105 vegetative growth Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
- C07H15/16—Lincomycin; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
- Y10S435/90—Streptomyces lincolnensis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/913—Aspergillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/913—Aspergillus
- Y10S435/917—Aspergillus niger
Definitions
- This invention relates to a novel process for the oxygenation of lincomycins to obtain the corresponding lincomycin sulfoxides. More particularly, this invention comprises a process whereby lincomycins, e.g., lincomycin, 7-epilincomycin (the epimer of lincomycin wherein the 7-hydroxy substituent is in the 7(S) position rather than the 7(R) position as in lincomycin itself), 7(S)-chloro-7-deoxy1incomycin and 7(R)- chloro-7-deoxylincomycin analogs thereof, and the corresponding acid addition salts thereof, are subjected to the oxygenating activity of certain micro-organisms to obtain the corresponding lincomycin sulfoxides, such as lincomycin sulfoxide, 7-epilincomycin sulfoxide, the respective 7(S)-
- R is methyl or ethyl
- R is alkyl of from two to eight carbon atoms, inclusive
- R is hydrogen or alkyl of from one to eight carbon atoms, inclusive
- X is hydroxy, chlorine or bromine.
- alkyl of from one to eight carbon atoms, inclusive are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and isomeric forms thereof.
- the wavy line appearing at the 4- position of the pyrrolidine ring is used to indicate that the group R can be position cis (below the plane of the ring) of trans (above the plane of the ring), with respect to the carbonyl group the wavy line appearing at the 7-position is used to indicate that both epimers are to be included, i.e., the configuration wherein the hydroxy, chloro or bromo group is located to the right of the vertical line as drawn or the (R) configuration wherein the hydroxy, chloro or bromo group is located to the left.
- the wavy line to the oxygen atom is used to indicate that the oxygen can be up or down.
- the compounds of Formulas l and II exist either in the pronotated or nonprotonated forms.
- the free bases can be converted to stable acid-addition salts in accordance with methods known in the art, for example, by neutralizing the free base with the appropriate acid to below about pH 7.0, and advantageously to about pH 2 to pH 6.
- Suitable acids for this purpose include hydrochloric, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, pamoic, chlolic, palmitic, mucic, camphoric, glutaric, glycolic, phthalic, tartaric,
- the lincomycin sulfoxides produced by the process of the present invention are known active antibacterial agents.
- active antibacterial agents For example see U.S. Pat. No. 3,382,230. They have in vitro and in vivo antibacterial activity and can be administered orally or parenterally to animals, including mammals, for the alleviation of bacterial infections especially those caused by Gram positive bacteria such as Staphylococcus aureus and Streptococcus hemolyticus.
- 7(S)-chloro-7-deoxylincomycin sulfoxide has in vivo antibacterial activity comparable to that of lincomycin and can be used in vivo for the same purposes and in the same manner as lincomycin.
- the compounds of the invention are particularly useful because of the relative low toxicity and their effectiveness in rapidly establishing high blood levels.
- microbiological process of this invention comprises subjecting a lincomycin of Formula 1 to the oxygenating activity of one of the following micro-organisms:
- Aspergillus niger ATCC 9029; which are available from known public sources such as the Northern Utilization Research and Development Branch, U.S. Department of Agriculture, Peoria, Ill. (NRRL); the American Type Culture Collection (ATCC), Washington. DC; Centraalbureau voor Schimmelcultures (CBS), Baarn, Holland; and The Commonwealth Mycological Institute (IMI), Kew, Surrey, England, as indicated above. ln the practice of this invention the species Streptomyces armenlosus, NRRL 3 I76 is especially advantageous.
- the bioconversion can be effected by a growing or resting culture of the micro-organism or by spores, washed cells or enzymes of the micro-organism.
- Culture of the micro-organism for the purpose and practice of this invention is in or on a medium favorable to its development.
- Sources of nitrogen and carbon should be present in the culture medium and an adequate sterile air supply should be maintained during the conversion, for example, by the conventional techniques of exposing a large surface of the medium to the air or by passing air through a submerged culture.
- Nitrogen in assimilable form can be provided by sources normally employed in such processes, such as corn steep liquor, cotton seed meal, soybean meal, yeast extracts, peptone, soluble or insoluble vegetable or animal protein, lactalbumin, casein, whey, distillers solubles, amino acids, nitrates and ammonium compounds, such as ammonium tartrate, nitrate, sulfate and the like.
- sources normally employed in such processes such as corn steep liquor, cotton seed meal, soybean meal, yeast extracts, peptone, soluble or insoluble vegetable or animal protein, lactalbumin, casein, whey, distillers solubles, amino acids, nitrates and ammonium compounds, such as ammonium tartrate, nitrate, sulfate and the like.
- Available carbon can also be provided by sources normally used in bioconversions such as carbohydrates, e.g., glucose,
- fructose sucrose, lactose, maltose, dextrines, starches; meat extracts, peptones, amino acids, proteins, fatty acids, glycerol, whey and the like.
- concentrates such as whey concentrate, corn steep liquor, grain mashes, cotton seed meal, and the like, or as mixtures of the above.
- sources of carbon can also serve as a source ofnitrogen.
- the medium can desirably have a pH before inoculation of between about pH 4 to about 8 though a higher or lower pH can be used.
- a temperature between about 25 to 32 C. is preferred for growth of the micro-organism, but higher or lower temperatures within a relatively wide range are suitable.
- the substrate compound (1 can be added to the culture during the growth period of the micro-organism as a single feed or by intermittent addition during the conversion period, or it can be added to the medium before or after sterilization or inoculation making appropriate adjustments for effects of pH and/r temperature upon the stability of the substrate used.
- the preferred, but not limiting, range of concentration of the substrate in the culture medium is about 50 500 mg. per liter. In the practice of this invention, it is convenient to add the substrate to the medium in the form ofa water-soluble acid addition salt.
- the temperature during the fermentation can be the same as that found suitable for growth of the micro-organism. It need be maintained only within such range as supports life, active growth or the enzyme activity of the micro-organism. A range of to 35 C. is preferred. A pH of about 6 to 8 is generally preferred for growth of the micro-organism during the bioconversion. Aeration can be effected by surface culture or preferably by use of submerged fermentation conditions with air sparging, in accordance with methods well-known in the art. The time required for oxygenation by the enzymatic system of the micro-organism employed can vary considerably. The range of about 2 to 120 hours is practical but not. limiting; 24 -72 hours is generally satisfactory. The progress of the bioconversion and its completion are conveniently determined by paper-strip chromatography, or thinfilm chromatography [Heftman, Chromatography (196] Reinhold Publishing Co., New York, N.Y.].
- oxygenation of the selected substrate can be effected under aerobic conditions by subjecting it to the activity of enzymes prepared from the micro-organism, to the action of spores of the micro-organism.
- Isolated enzyme preparations can be prepared in accordance with the general procedures disclosed by Zuidweg et al., Biochim, Biophy. Acta, 58, 131-133 (1962).
- the bioconversion can be effected with spores in accordance with the general process disclosed in U.S. Pat. Nos. 3,031,379 and 3,031,382.
- the separation of washed cells from the fermentation medium is well-known in the art, see for example, U.S. Pat. No. 2,8 31,789.
- the bioconversion may be c0nducted according to the principles discussed above, with addition of preformed lincomycin or an acid addition salt thereof to the oxygenating milieu, as borne out by oxygenations in which added radioactive lincomycin is found to be bioconverted to radioactive lincomycin sulfoxide.
- Lincomycin in produced S. [incolnensis as described in U.S. Pat. No. 3,086,9l2. It has been found in the present invention that lincomycin thus accumulated from the lincomycinbiosynthesis activities of S. Iincolnensis can be bioconverted to lincomycin sulfoxide by the simple agency of extending the time of the lincomycin fermentation beyond the time necessary for maximal lincomycin accumulation, for example, by use of a total fermentation time of about 12 days as compared to a time of about 6 days for maximal lincomycin production.
- oxygenating activity means the enzymatic action of a growing or resting culture of the micro-organism which effects introduction of oxygen into the molecule of the substrate under fermentation conditions.
- the resulting oxygenated products 11 are recovered from the fermentation beer by conventional methods.
- the whole beer can be extracted with a water-immiscible organic solvent such as methylene chloride, chloroform, carbon tetrachloride, ethylene chloride, trichlorethylene, ether, amyl acetate, benzene, and the like, or the beer and mycelium can be separated by conventional methods such as centrifugation or filtration, and then separately extracted with suitable solvents.
- the mycelium can be extracted with either water-miscible or water-immiscible solvents or in cases where little or no product is contained in the mycelium, it can be merely washed with water and the wash water added to the beer filtrate.
- the beer, free of mycelium, can then be extracted with water-immiscible solvents such as those listed above.
- the extracts are combined, dried over a drying agent such as anhydrous sodium sulfate, and the solvent removed by conventional methods such as evaporation or distillation at atmospheric or reduced pressure.
- the products can be adsorbed from the beer on an adsorbent resin or on carbon and the products eluted with a polar organic solvent such as methanol, ethanol, acetone, ethyl acetate, methyl ethyl ketone, aqueous mixtures thereof, and the like.
- a polar organic solvent such as methanol, ethanol, acetone, ethyl acetate, methyl ethyl ketone, aqueous mixtures thereof, and the like.
- the products 11 obtained by either the extraction or elution procedures can be isolated and further purified by conventional methods, e.g., chromatography and/or crystallization, and the like.
- the products [1 can be obtained as free base or as acid addition salts in accordance with procedures hereintofore disclosed.
- Example I 7(S)-Chloro-7-deoxylincomycin sulfoxide A vegetative seed from a culture of Streptomyces armentorus, NRRL 3176, is prepared by growing the culture for 3 days at about 28 C. in reciprocating shake flasks (250 r.p.m., stroke 2.5 cm.) on a medium consisting of 25 g. per liter of Cerelose (glucosemonohydrate) and 25 g. per liter of Phar mamedia (Cotton Seed Flour, Traders Milling (20., P. O. Box i837, Fort Worth, Tex. 76100) in tap water. The medium is sterilized prior to inoculation.
- the pH prior to sterilization is i
- the resulting seed is used to inoculate a medium consisting of 20 g. per liter of black strap molasses, 30 g. per liter of starch, 15 g. per liter of fish meal and 15 g. per liter of Pharamamedia.
- Lard oil (5 ml. per liter) is added to prevent foaming.
- the medium is adjusted to pH 7.2 and 40 shake flasks (500 m1.) are prepared each containing ml. of the medium.
- the shake flasks are sterilized (pH after sterilization is 6.2) and are inoculated with 5 ml. of the vegetative seed (prepared above) per 100 ml. of medium.
- the culture is then allowed to grow for 48 hours on a rotary shaker (250 r.p.m., stroke 2.5 cm.) at about 28 C.
- a rotary shaker 250 r.p.m., stroke 2.5 cm.
- 50 mg. of 7(S)chloro-7-de0xylincomycin hydrochloride is added to each shake flask and the fermentation is continued for an additional period of about 72 hours.
- the contents of the flasks are then pooled (about 4 liters), diatomaceous earth is added and the beer and mycelium are separated by filtration.
- the filter cake is washed with about 1 l. of water and the wash water is added to the clear beer.
- the remaining residue (800 mg.) is distributed in an all glass countercurrent distribution apparatus using a solvent system consisting of equal volumes of n-butanol and water.
- the pH of the lower phase of the first tubes is adjusted to 4.0 using aqueous hydrochloric acid.
- the distribution is analyzed by thin layer chromatography. Those fractions which show 7(S)-chloro-7-deoxylincomycin sulfoxide hydrochloride to be the major product are triturated with acetone to give crystalline 7(S)-chloro-7-deoxylincomycin sulfoxide hydrochloride (about 440 mg.).
- the product is further identified by comparison with an authentic sample of the same compound using NMR spectra, mass spectra and thin layer chromatography.
- the samples are then checked for bioconversion by paper chromatography. Aliquots of 2 to 5 [.Ll of the filtered beer from each of the bioconversions are applied on filter paper (Whatman No. 3 HR, 18 X 13 mm.). The bioconversion products are separated from the starting material by ascending chromatography using a mixture of ethyl acetate; acetone; water (815:1 vol./vol.) as solvent system.
- the other lincomycins of formula I, above, or acid addition salts thereof for example, those compounds listed in example 1, above, can be converted to the corresponding sulfoxides of formula ll or the acid addition salts thereof.
- sterile seed medium consisting of 10 g. per liter Cerelose, 10 g. per liter torula yeast (St. Regis Paper Co., Lake States Division, Rhinelander, Wis.), g. per liter distillers solubles (National Distillers Products Co., New York, N.Y.) and 4 g. per liter of NaCl is made up in a 401iter seed tank and adjusted to pH 7.2 with NaOH.
- One g. per liter of CaCO and 2 ml. per liter of lard oil (antifoam) are added and the medium is sterilized at 121 C. for 30 minutes. Upon cooling by use of cold jacket water it is inoculated with 100 rnls.
- Two hundred fifty liters of the following sterile fermentation medium are prepared in a fermentor tank of about 380 liters total volume: Cerelose, 3.75 kg.; cornstarch, 10 kg.; Pharmamedia (an industrial grade of cottonseed flour produced by Traders Milling Co., Fort Worth, Tex.), 6.25 kg.; blackstrap molasses, 5.0 kg.; K SO (industrial grade) 0.5 kg; water to about 225 liters; NaOl-l to pH 7.25, water to give 250 liters after sterilization.
- the medium is sterilized at 123 C. for 30 minutes and cooled by cold water jacket cooling. Poststerilization pH 7.30.
- This sterile fermentation medium is inoculated with 12.5 liters (Spercent vol./vo1.) of the above seed.
- the fermentation is run for 282 hours at 29 C. with agitation by flat-bladed impellor at 280 rpm. and sparging with sterile air at 250 liters per minute.
- the polished beer (205 liters) is extracted three times with methylene chloride (about 100 liters each time) to yield 290 liters of pooled extract and 200 liters of half-spent beer.
- the half-spent beer is adjusted to pH 10 with NaOH and extracted three times with n-butanol (about 75 liters each time) to yield 210 liters of pooled butanol extract.
- the butanol is evaporated, the residue dissolved in water and concentrated to a dry solid l, 437.4 g. Paper chromatogram analysis indicates the presence of lincomycin sulfoxide lincomycin, and other impurities.
- Papergram analysis shows that lincomycin sulfoxide is segregated in tubes 20 to 37. These are pooled and evaporated to yield solid [11. Solid lll is now dissolved in a minimal volume of methanol and distributed in a countercurrent distribution apparatus 10 ml. per phase, solvent watermbutanol 1:1 voL/vol.) for 1,000 transfers. Lincomycin sulfoxide is found to be segregated in tubes 70 to 99. These tubes are pooled and evaporated to dryness. The residue is dissolved and mixed with diethyl ether. A precipitate appears which is isolated by filtration and dried. This solid is dissolved in a minimal volume of methanol and redistributed in the countercurrent apparatus as above for 1,900 transfers. Tubes 85 to are now found to contain only lincomycin sulfoxide by papergram examination. These tubes are pooled and the pools are evaporated to dryness to yield about 600 mg. of lincomycin sulfoxide.
- the following sterile synthetic fermentation medium may be used: Per liter, glucose, 30 g.; sodium citrate, 3 g.; ZnS0,,-7H O, 0.001 g.; FeSO.,-7l-l 0, 0.01 g.; MGGSO l g.; KgHPOq, 2.5 g.; NaCl, 0.5 g. and Nl-liNO 2 g.
- This medium dispensed in 100-ml. portions in shake flasks, is advantageous for the making of small amounts of lincomycin sulfoxide. After inoculation such flasks can be shaken on a 250 rpm. rotary shaker, 2.5 inch stroke, at 28 C. for about 12 days.
- R is methyl or ethyl
- R is an alkyl of from two to eight carbon atoms, inclusive
- R is hydrogen or alkyl of from one to eight carbon atoms, inclusive
- X is hydroxyl, chlorine or bromine, or an acid addition salt thereof, which comprises subjecting a compound of the formula:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A microbiological process for the oxygenation of lincomycins to obtain the corresponding lincomycin sulfoxides which are known active antibacterial agents.
Description
United States Patent Inventors Alexander D. Argoudelis;
Donald J. Mason, both of Kalamazoo, Mich.
Oct. 21 196 8 Oct. 26, 197 1 The Upjohn Company Kalamazoo, Mich.
Appl. No. Filed Patented Assignee PRODUCTION OF LINCOMYCIN SULFOXIDE 6 Claims, No Drawings U.S. Cl 195/80, 195/29, 195/81, 260/210 R Int. Cl C12d 9/00 Field of Search .i 195/80, 81, 29; 260/210 References Cited UNITED STATES PATENTS 7/1952 Murray et al 195/51 2/1956 Murray et al. 195/51 4/1963 Bergy et a1 195/80 X 4/1968 Argoudelis et a1... 195/80 X 5/1968 Magerlein 260/210 Primary Examiner-Joseph M. Golian Allomeys- Eugene O. Retter and Willard L. Cheesman ABSTRACT: A microbiological process for the oxygenation oflincomycins to obtain the corresponding lincomycin sulfoxides which are known active antibacterial agents.
PRODUCTION OF LINCOMYCIN SULFOXIDE SUMMARY OF THE INVENTION This invention relates to a novel process for the oxygenation of lincomycins to obtain the corresponding lincomycin sulfoxides. More particularly, this invention comprises a process whereby lincomycins, e.g., lincomycin, 7-epilincomycin (the epimer of lincomycin wherein the 7-hydroxy substituent is in the 7(S) position rather than the 7(R) position as in lincomycin itself), 7(S)-chloro-7-deoxy1incomycin and 7(R)- chloro-7-deoxylincomycin analogs thereof, and the corresponding acid addition salts thereof, are subjected to the oxygenating activity of certain micro-organisms to obtain the corresponding lincomycin sulfoxides, such as lincomycin sulfoxide, 7-epilincomycin sulfoxide, the respective 7(S)-chloro- 7-deoxylincomycin sulfoxide, 7(R)- chloro-7-deoxylincomycin sulfoxide, analogs thereof, and the corresponding acid addition salts thereof.
DETAILED DESCRIPTION OF THE INVENTION The microbiological process of this invention is represented by the following reaction scheme:
II OH wherein R is methyl or ethyl, R is alkyl of from two to eight carbon atoms, inclusive, R is hydrogen or alkyl of from one to eight carbon atoms, inclusive, and X is hydroxy, chlorine or bromine.
Examples of alkyl of from one to eight carbon atoms, inclusive, are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, and octyl and isomeric forms thereof.
In this application, the wavy line appearing at the 4- position of the pyrrolidine ring is used to indicate that the group R can be position cis (below the plane of the ring) of trans (above the plane of the ring), with respect to the carbonyl group the wavy line appearing at the 7-position is used to indicate that both epimers are to be included, i.e., the configuration wherein the hydroxy, chloro or bromo group is located to the right of the vertical line as drawn or the (R) configuration wherein the hydroxy, chloro or bromo group is located to the left. The wavy line to the oxygen atom is used to indicate that the oxygen can be up or down.
The compounds of Formulas l and II exist either in the pronotated or nonprotonated forms. The free bases can be converted to stable acid-addition salts in accordance with methods known in the art, for example, by neutralizing the free base with the appropriate acid to below about pH 7.0, and advantageously to about pH 2 to pH 6. Suitable acids for this purpose include hydrochloric, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, pamoic, chlolic, palmitic, mucic, camphoric, glutaric, glycolic, phthalic, tartaric,
lauric, stearic, salicyclic, 3-phenylsalicyclic, S-phenylsalicyclic, 3-methylglutaric, orthosulfobenzoic, cyclopentanepropionic, l, 2-cyclohexane-dicarboxylic, 4-cyclohexanecarboxylic, octadecenylsuccinic, octenylsuccinic,
methanesulfonic, benzenesulfonic, helianthic, Reineckes, dimethyldithiocarbamic, cyclohexylsulfamic, hexadecylsulfamic, octadecylsulfamic, sorbic, monochloroacetic, undecylenic, 4-hydroxyazobenzene-4-sulfonic, octyldecylsulfuric, picric, benzoic, cinnamic, and like acids.
The lincomycin sulfoxides produced by the process of the present invention, represented by Formula 11, above, and the acid addition salts thereof are known active antibacterial agents. For example see U.S. Pat. No. 3,382,230. They have in vitro and in vivo antibacterial activity and can be administered orally or parenterally to animals, including mammals, for the alleviation of bacterial infections especially those caused by Gram positive bacteria such as Staphylococcus aureus and Streptococcus hemolyticus. For example, 7(S)-chloro-7-deoxylincomycin sulfoxide has in vivo antibacterial activity comparable to that of lincomycin and can be used in vivo for the same purposes and in the same manner as lincomycin. The compounds of the invention are particularly useful because of the relative low toxicity and their effectiveness in rapidly establishing high blood levels.
The starting compounds of Formula 1, above, and the acid addition salts thereof, are known in the art, see for example, U.S. Pat. No. 3,380,992, Belgium Pat. Nos. 676,202 and 705,345 issued Aug. 8, 1966 and Apr. 19, I968 respectively; French Pat. No. 1,474,237, issued Feb. 13, 1967; South African Pat. Nos. 66/0319 and 66/0320, issued Jan. 25, 1967 and Magerlein et al., Chemical Modifications of Lincomycin", Antibiotics and Chemotherapy 1966), page 727 ff.
The microbiological process of this invention comprises subjecting a lincomycin of Formula 1 to the oxygenating activity of one of the following micro-organisms:
Streplomyces armentosus, NRRL 3176;
Streptomyces spectabilis, NRRL 2494;
Streptomyces spectabilis, NRRL 2792;
Streptomyces lincolnensis, NRRL 2936',
Anixiopsis multispora, CBS;
Aspergillus citricus, IMI 15954;
Aspergillus niger, ATCC 8740; and
Aspergillus niger, ATCC 9029; which are available from known public sources such as the Northern Utilization Research and Development Branch, U.S. Department of Agriculture, Peoria, Ill. (NRRL); the American Type Culture Collection (ATCC), Washington. DC; Centraalbureau voor Schimmelcultures (CBS), Baarn, Holland; and The Commonwealth Mycological Institute (IMI), Kew, Surrey, England, as indicated above. ln the practice of this invention the species Streptomyces armenlosus, NRRL 3 I76 is especially advantageous.
The operational conditions and reaction procedures for the bioconversion process of this invention are advantageously those known in the art of bioconversion as illustrated in Murray et al., US. Pat. Nos. 2,602,769 and 2,735,800.
In the practice of this invention, the bioconversion can be effected by a growing or resting culture of the micro-organism or by spores, washed cells or enzymes of the micro-organism.
Culture of the micro-organism for the purpose and practice of this invention is in or on a medium favorable to its development. Sources of nitrogen and carbon should be present in the culture medium and an adequate sterile air supply should be maintained during the conversion, for example, by the conventional techniques of exposing a large surface of the medium to the air or by passing air through a submerged culture.
Nitrogen in assimilable form can be provided by sources normally employed in such processes, such as corn steep liquor, cotton seed meal, soybean meal, yeast extracts, peptone, soluble or insoluble vegetable or animal protein, lactalbumin, casein, whey, distillers solubles, amino acids, nitrates and ammonium compounds, such as ammonium tartrate, nitrate, sulfate and the like.
Available carbon can also be provided by sources normally used in bioconversions such as carbohydrates, e.g., glucose,
fructose, sucrose, lactose, maltose, dextrines, starches; meat extracts, peptones, amino acids, proteins, fatty acids, glycerol, whey and the like. These materials may be used either in a purified state of as concentrates such as whey concentrate, corn steep liquor, grain mashes, cotton seed meal, and the like, or as mixtures of the above. Many of the above sources of carbon can also serve as a source ofnitrogen. V
The medium can desirably have a pH before inoculation of between about pH 4 to about 8 though a higher or lower pH can be used. A temperature between about 25 to 32 C. is preferred for growth of the micro-organism, but higher or lower temperatures within a relatively wide range are suitable.
The substrate compound (1 can be added to the culture during the growth period of the micro-organism as a single feed or by intermittent addition during the conversion period, or it can be added to the medium before or after sterilization or inoculation making appropriate adjustments for effects of pH and/r temperature upon the stability of the substrate used. The preferred, but not limiting, range of concentration of the substrate in the culture medium is about 50 500 mg. per liter. In the practice of this invention, it is convenient to add the substrate to the medium in the form ofa water-soluble acid addition salt.
The temperature during the fermentation can be the same as that found suitable for growth of the micro-organism. It need be maintained only within such range as supports life, active growth or the enzyme activity of the micro-organism. A range of to 35 C. is preferred. A pH of about 6 to 8 is generally preferred for growth of the micro-organism during the bioconversion. Aeration can be effected by surface culture or preferably by use of submerged fermentation conditions with air sparging, in accordance with methods well-known in the art. The time required for oxygenation by the enzymatic system of the micro-organism employed can vary considerably. The range of about 2 to 120 hours is practical but not. limiting; 24 -72 hours is generally satisfactory. The progress of the bioconversion and its completion are conveniently determined by paper-strip chromatography, or thinfilm chromatography [Heftman, Chromatography (196] Reinhold Publishing Co., New York, N.Y.].
Alternatively, oxygenation of the selected substrate can be effected under aerobic conditions by subjecting it to the activity of enzymes prepared from the micro-organism, to the action of spores of the micro-organism. Isolated enzyme preparations can be prepared in accordance with the general procedures disclosed by Zuidweg et al., Biochim, Biophy. Acta, 58, 131-133 (1962). The bioconversion can be effected with spores in accordance with the general process disclosed in U.S. Pat. Nos. 3,031,379 and 3,031,382. The separation of washed cells from the fermentation medium is well-known in the art, see for example, U.S. Pat. No. 2,8 31,789.
In the case of the bioconversion of lincomycin itself to lincomycin sulfoxide by use of the oxygenating activity of Streptomyces lincolnensis, the bioconversion may be c0nducted according to the principles discussed above, with addition of preformed lincomycin or an acid addition salt thereof to the oxygenating milieu, as borne out by oxygenations in which added radioactive lincomycin is found to be bioconverted to radioactive lincomycin sulfoxide.
Lincomycin in produced S. [incolnensis as described in U.S. Pat. No. 3,086,9l2. It has been found in the present invention that lincomycin thus accumulated from the lincomycinbiosynthesis activities of S. Iincolnensis can be bioconverted to lincomycin sulfoxide by the simple agency of extending the time of the lincomycin fermentation beyond the time necessary for maximal lincomycin accumulation, for example, by use of a total fermentation time of about 12 days as compared to a time of about 6 days for maximal lincomycin production.
The term oxygenating activity as used throughout this specification means the enzymatic action of a growing or resting culture of the micro-organism which effects introduction of oxygen into the molecule of the substrate under fermentation conditions.
After completion of the fermentation, the resulting oxygenated products 11 are recovered from the fermentation beer by conventional methods. For example, the whole beer can be extracted with a water-immiscible organic solvent such as methylene chloride, chloroform, carbon tetrachloride, ethylene chloride, trichlorethylene, ether, amyl acetate, benzene, and the like, or the beer and mycelium can be separated by conventional methods such as centrifugation or filtration, and then separately extracted with suitable solvents. The mycelium can be extracted with either water-miscible or water-immiscible solvents or in cases where little or no product is contained in the mycelium, it can be merely washed with water and the wash water added to the beer filtrate. The beer, free of mycelium, can then be extracted with water-immiscible solvents such as those listed above. The extracts are combined, dried over a drying agent such as anhydrous sodium sulfate, and the solvent removed by conventional methods such as evaporation or distillation at atmospheric or reduced pressure.
Alternatively, the products can be adsorbed from the beer on an adsorbent resin or on carbon and the products eluted with a polar organic solvent such as methanol, ethanol, acetone, ethyl acetate, methyl ethyl ketone, aqueous mixtures thereof, and the like.
The products 11 obtained by either the extraction or elution procedures can be isolated and further purified by conventional methods, e.g., chromatography and/or crystallization, and the like. The products [1 can be obtained as free base or as acid addition salts in accordance with procedures hereintofore disclosed.
The following examples are intended to illustrate the process of this invention. The examples are for the purpose of illustrating the best mode contemplated of carrying out the invention and to supplement the foregoing disclosure with additional descriptions of the manner and process of carrying out the invention so as to further enable workers skilled in the art to do so, but they are not to be construed as limiting.
Example I 7(S)-Chloro-7-deoxylincomycin sulfoxide A vegetative seed from a culture of Streptomyces armentorus, NRRL 3176, is prepared by growing the culture for 3 days at about 28 C. in reciprocating shake flasks (250 r.p.m., stroke 2.5 cm.) on a medium consisting of 25 g. per liter of Cerelose (glucosemonohydrate) and 25 g. per liter of Phar mamedia (Cotton Seed Flour, Traders Milling (20., P. O. Box i837, Fort Worth, Tex. 76100) in tap water. The medium is sterilized prior to inoculation. The pH prior to sterilization is i The resulting seed is used to inoculate a medium consisting of 20 g. per liter of black strap molasses, 30 g. per liter of starch, 15 g. per liter of fish meal and 15 g. per liter of Pharamamedia. Lard oil (5 ml. per liter) is added to prevent foaming. The medium is adjusted to pH 7.2 and 40 shake flasks (500 m1.) are prepared each containing ml. of the medium. The shake flasks are sterilized (pH after sterilization is 6.2) and are inoculated with 5 ml. of the vegetative seed (prepared above) per 100 ml. of medium.
The culture is then allowed to grow for 48 hours on a rotary shaker (250 r.p.m., stroke 2.5 cm.) at about 28 C. At the end of the 48 hour growth period, 50 mg. of 7(S)chloro-7-de0xylincomycin hydrochloride is added to each shake flask and the fermentation is continued for an additional period of about 72 hours. The contents of the flasks are then pooled (about 4 liters), diatomaceous earth is added and the beer and mycelium are separated by filtration. The filter cake is washed with about 1 l. of water and the wash water is added to the clear beer.
The combined clear beer and wash thus obtained (4.8 L.) is adjusted to pH 10.0 with aqueous sodium hydroxide and extracted three times with 1.600 ml. portions of methylene chloride. The combined extracts are evaporated to dryness to give 1.0 g. of crude 7(S)-chloro-7-deoxylincomycin sulfoxide, which is purified by conventional methods such as chromatography.
An aliquot (200 mg.) of the dried residue thus obtained is dissolved in 5 ml. of l N methanolic hydrogen chloride and the solution thus obtained is mixed with ether to give a precipitate which is removed by filtration, washed with ether and dried. The dried product thus obtained is assayed by thin layer chromatography [silica gel 6., methyl ethyl ketoneacetone water (140:40z22 Vol./Vol.)] and shows the presence of 7(S)-chloro-7-deoxylincomycin hydrochloride and 7(8)- chloro-7-deoxylincomycin sulfoxide hydrochloride as the main components.
The remaining residue (800 mg.) is distributed in an all glass countercurrent distribution apparatus using a solvent system consisting of equal volumes of n-butanol and water. The pH of the lower phase of the first tubes is adjusted to 4.0 using aqueous hydrochloric acid. After about 500 transfers, the distribution is analyzed by thin layer chromatography. Those fractions which show 7(S)-chloro-7-deoxylincomycin sulfoxide hydrochloride to be the major product are triturated with acetone to give crystalline 7(S)-chloro-7-deoxylincomycin sulfoxide hydrochloride (about 440 mg.). The product is further identified by comparison with an authentic sample of the same compound using NMR spectra, mass spectra and thin layer chromatography.
An analytical sample of the 7(S)-chloro-7-deoxylincomycin sulfoxide hydrochloride product from the above bioconversion gives the following analysis:
C,43.63;H,7.27;N,5.66; 5,6.46; Cl, 14.34
Found C,42.62;H,7.38;N,5.9l; 5.6.32;
Mol. Wt. ealcd. for the free base: 440
M01. Wt. found for the free base: 440 (by mass spectrometry) Other acids such as those hereintofore listed can be used in place of hydrochloric acid to obtain the corresponding acid addition salt of 7(S)-chloro-7-deoxylincomycin sulfoxide.
In the same manner, the following micro-organisms:
Slreptomyces spectabilis, NRRL 2494;
Streptomyces spectabilis, NRRL 2792;
Streptomyces lincolnesis, NRRL 2936;
Artixiopsis multispora, CBS;
Aspergillus cilricus, lMl 15954;
Aspergillus niger, ATCC 8740; and
Aspergillus niger, ATCC 9029;
are used in place of Streptomyces armentosus, NRRL 3 l 76 to obtain 7(S)-chloro 7-deoxylincomycin sulfoxide or one of its acid addition salts.
In the same manner following the procedure of example 1, other lincomycins of formula l can be substituted as the substrate in place of 7(S)-chloro-7-deoxylincomycin hydrochloride to obtain the corresponding lincomycin sulfoxide of formula II. The following conversions are representative of further substrate materials which can be used, either as free bases or acid addition salts thereof, with reference to formula l, in this invention to obtain the corresponding compounds of formula II as free bases or acid addition salts thereof.
trans-i-propyl (Sl-Cl methyl methyl transm-butyl (S )-C1 methyl methyl trans-n-butyl (R)-OH ethyl methyl trans-n-butyl (R)-C1 methyl methyl cis-n-butyl (S)-Cl methyl methyl trans-n-pentyl (Sl-Cl methyl methyl trans-n-pentyl (S)-Cl methyl ethyl trans-n-pentyl (S)-Cl methyl hydrogen trans-n-pentyl (S)-Br methyl methyl trans-n-pentyl (TU-OH methyl methyl trans-n-pentyl (R)-OH methyl ethyl trans-rt-pentyl (R)-OH methyl hydrogen trans-n-pentyl (S) Br ethyl methyl trans-n-pentyl (R)-Cl methyl methyl trans-n-pentyl (S)-OH methyl methyl cis-n-pentyl (S)-Cl methyl methyl trans-n-hexyl (S)-Cl methyl methyl trans-n-hexyl (S)-Cl methyl ethyl trans-n-hexyl (SJ-Cl methyl hydrogen trans-n-hexyl (S)-Cl ethyl methyl transm-hexyl (R)-Cl methyl methyl cis-nhexyl (S)-Cl methyl methyl trans-i-heptyl (R)-OH methyl methyl trans-n-heptyl (S)-Cl methyl methyl trans-n-heptyl (R)-Cl methyl methyl cis-n-heptyl (S)-Cl methyl methyl cis-n-hcptyl lR)-Br methyl methyl transm-octyl (S)-Cl methyl methyl trans-n-octyl (S)-Cl ethyl methyl trans-n-Octyl (Rj-OH ethyl methyl trans-n-octyl (R)-Cl methyl methyl trunS-i-octyl (S)-Ct methyl methyl cis-moctyl (SJ-Cl methyl methyl Example 2 7(S)-Chloro-7-deoxylincomycin sulfoxide A medium is prepared consisting of 2 g. of malt extract, 0.1 g. of peptone and 2 g. of Cerelose diluted to lOO ml. Five 20- ml. portions of this medium in l25-ml. flasks are sterilized and each is inoculated with a 72 hour vegetative growth of one of the following micro-organisms:
Streplomyces spectabilis, NRRL 2494;
Srreplomyces spectabilt's, NRRL 2792;
Anixiopris multirpora, CBS;
AAspergillus citricus, [Ml 15954;
Aspergillus niger, ATCC 8740; and
Aspergt'llus niger, ATCC 9029.
After 2 to 5 days when a heavy growth of mycelium is apparent by visual observations 50 to lOO mg. of 7(S)-chloro-7- deoxylincomycin hydrochloride are added to each flask and the incubation of each flask is continued for an additional period offrom 3 to 5 days.
The samples are then checked for bioconversion by paper chromatography. Aliquots of 2 to 5 [.Ll of the filtered beer from each of the bioconversions are applied on filter paper (Whatman No. 3 HR, 18 X 13 mm.). The bioconversion products are separated from the starting material by ascending chromatography using a mixture of ethyl acetate; acetone; water (815:1 vol./vol.) as solvent system. Comparison of these papergrams with a papergram made in the same manner from an authentic mixture of 7(S)-chloro-7-deoxylincomycin and 7(S)-chloro-7-deoxylincomycin sulfoxide shows that each of the bioconversions produce 7(S)-chloro-7-deoxylincomycin sulfoxide as the bioconversion product.
Likewise, using the micro-organisms listed above, the other lincomycins of formula I, above, or acid addition salts thereof, for example, those compounds listed in example 1, above, can be converted to the corresponding sulfoxides of formula ll or the acid addition salts thereof.
Example 3 Lincomycin sulfoxide Sterile preseed medium consisting of l0 g. per liter Cerelose, 5 g. per liter Yeastolac (Partial autolysate of brewers yeast cells, blended with milk solids, Vico Products Co., Chicago, Ill.) and 5 g. per liter N-Z Amine B (Casein hydrolysate, Sheffield Division of National Dairy Products, Norwich, N.Y.), adjusted to pH 7.2 with NaOH, is dispensed in ml. portions in 500-ml. widemouthed Earlenmeyer shake flasks and sterilized at l2l C. for 30 minutes. The cooled flasks are inoculated with Streptomyces lincolnensis, NRRL2936 and incubated on a reciprocating shaker at 28 C. for 2 days to yield vegetative preseed.
Twenty liters of sterile seed medium consisting of 10 g. per liter Cerelose, 10 g. per liter torula yeast (St. Regis Paper Co., Lake States Division, Rhinelander, Wis.), g. per liter distillers solubles (National Distillers Products Co., New York, N.Y.) and 4 g. per liter of NaCl is made up in a 401iter seed tank and adjusted to pH 7.2 with NaOH. One g. per liter of CaCO and 2 ml. per liter of lard oil (antifoam) are added and the medium is sterilized at 121 C. for 30 minutes. Upon cooling by use of cold jacket water it is inoculated with 100 rnls. of the above preseed and incubated for 2 days at 28 C. with stir ring by flat-bladed impellor at 400 r.p.m. and sparging with sterile air at a rate of standard liters per minute, to yield vegetative seed.
Two hundred fifty liters of the following sterile fermentation medium are prepared in a fermentor tank of about 380 liters total volume: Cerelose, 3.75 kg.; cornstarch, 10 kg.; Pharmamedia (an industrial grade of cottonseed flour produced by Traders Milling Co., Fort Worth, Tex.), 6.25 kg.; blackstrap molasses, 5.0 kg.; K SO (industrial grade) 0.5 kg; water to about 225 liters; NaOl-l to pH 7.25, water to give 250 liters after sterilization. The medium is sterilized at 123 C. for 30 minutes and cooled by cold water jacket cooling. Poststerilization pH 7.30. This sterile fermentation medium is inoculated with 12.5 liters (Spercent vol./vo1.) of the above seed. The fermentation is run for 282 hours at 29 C. with agitation by flat-bladed impellor at 280 rpm. and sparging with sterile air at 250 liters per minute.
Whole fermented beer 186.5 kg.) obtained as above is suction-filtered with the use of 4percent (wt./vol.) Celatom FW-40 (Eagle Pitcher Industries, Cincinnati, Ohio) filter aid. The resulting clear beer is adjusted to pH 4 with concentrated H S0,, let stand for nearly 2 hours and refiltered with suction upon addition of lpercent (wt./vol.) Celatom FW-40 to give polished beer.
The polished beer (205 liters) is extracted three times with methylene chloride (about 100 liters each time) to yield 290 liters of pooled extract and 200 liters of half-spent beer. The half-spent beer is adjusted to pH 10 with NaOH and extracted three times with n-butanol (about 75 liters each time) to yield 210 liters of pooled butanol extract. The butanol is evaporated, the residue dissolved in water and concentrated to a dry solid l, 437.4 g. Paper chromatogram analysis indicates the presence of lincomycin sulfoxide lincomycin, and other impurities.
About 400 g. of dry solid 1 is triturated with 8 liters of acetone. Insoluble materials are filtered off. The filtrate is mixed with an equal volume of diethyl ether. A precipitate which appears is filtered off. The filtrate is concentrated to dryness to give solid 11.
Further purification is achieved by counter-double-current distribution in the solvent system n-butanolzwater 1:1 (vol./vol.). Typically, 20 g. of solid II is dissolved in 100 ml. of the lower phase of this solvent system. The pH is adjusted to 4.2 with HCl. Upper phase is added and the mixture is placed in four tubes of an all glass counter-double-current distribution apparatus, each tube having an operating liquid capacity of 25 mls. After 140 transfers, the lincomycin sulfoxide is found by papergrams to be contained primarily in tubes 20 to 40. These are pooled and evaporated, and the resulting solid is redistributed in a second counter-double-current distribution as above. Papergram analysis shows that lincomycin sulfoxide is segregated in tubes 20 to 37. These are pooled and evaporated to yield solid [11. Solid lll is now dissolved in a minimal volume of methanol and distributed in a countercurrent distribution apparatus 10 ml. per phase, solvent watermbutanol 1:1 voL/vol.) for 1,000 transfers. Lincomycin sulfoxide is found to be segregated in tubes 70 to 99. These tubes are pooled and evaporated to dryness. The residue is dissolved and mixed with diethyl ether. A precipitate appears which is isolated by filtration and dried. This solid is dissolved in a minimal volume of methanol and redistributed in the countercurrent apparatus as above for 1,900 transfers. Tubes 85 to are now found to contain only lincomycin sulfoxide by papergram examination. These tubes are pooled and the pools are evaporated to dryness to yield about 600 mg. of lincomycin sulfoxide.
The lincomycin sulfoxide thus obtained is identical to an authentic sample on thin-layer chromatography Silica gel 6., (Merck Dai'mstadt), methyl ethyl ketone:acetone:water :40:22 by volume]; by infrared chromatography and by nuclear magnetic resonance. Elemental analysis (as hydrochloride acid addition salt) is:
Calculated: C,45.33;H, 7.83; N,5.87; S, 6.75; Cl, 7.44 Found: C,45.22;!1,7.88;N,6.28;S,4.43;Cl,6.07
(Calculated for C H N 0 S' HC1-H 0) Alternatively, the following sterile synthetic fermentation medium may be used: Per liter, glucose, 30 g.; sodium citrate, 3 g.; ZnS0,,-7H O, 0.001 g.; FeSO.,-7l-l 0, 0.01 g.; MGGSO l g.; KgHPOq, 2.5 g.; NaCl, 0.5 g. and Nl-liNO 2 g. This medium, dispensed in 100-ml. portions in shake flasks, is advantageous for the making of small amounts of lincomycin sulfoxide. After inoculation such flasks can be shaken on a 250 rpm. rotary shaker, 2.5 inch stroke, at 28 C. for about 12 days.
We claim:
1. The process for the production ofa lincomycin sulfoxide of the formula:
IUI/ R OH wherein R is methyl or ethyl, R, is an alkyl of from two to eight carbon atoms, inclusive, R is hydrogen or alkyl of from one to eight carbon atoms, inclusive, and X is hydroxyl, chlorine or bromine, or an acid addition salt thereof, which comprises subjecting a compound of the formula:
5. The process of claim 1, wherein 7(S)-chloro-7-deoxylincomycin hydrochloride is subjected to the oxygenating activity of Streptomyces armentosur, NRRL 3176, in an aqueous nutrient medium under submerged fermentation conditions to obtain 7(S)-chloro-7-deoxylincomycin sulfoxide.
6. The process of claim 1, wherein lincomycin hydrochloride is subjected to the oxygenating activity of Streptomyces lincolnensis, NRRL 2936, in an aqueous nutrient medium under submerged fermentation conditions to obtain lincomycin sulfoxide.
Claims (5)
- 2. The process of claim 1, wherein the oxygenation is carried out under submerged fermentation conditions and the bioconversion is continued until a substantial amount of oxygenated product is produced.
- 3. The process of claim 1, wherein the oxygenation is carried out in an aqueous nutrient medium under aerobic fermentation conditions.
- 4. The process of claim 1, wherein the oxygenation is carried out in an aqueous nutrient medium under submerged fermentation conditions with Streptomyces armentosus, NRRL 3176.
- 5. The process of claim 1, wherein 7(S)-chloro-7-deoxylincomycin hydrochloride is subjected to the oxygenating activity of Streptomyces armentosus, NRRL 3176, in an aqueous nutrient medium under submerged fermentation conditions to obtain 7(S)-chloro-7-deoxylincomycin sulfoxide.
- 6. The process of claim 1, wherein lincomycin hydrochloride is subjected to the oxygenating activity of Streptomyces lincolnensis, NRRL 2936, in an aqueous nutrient medium under submerged fermentation conditions to obtain lincomycin sulfoxide.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76939568A | 1968-10-21 | 1968-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3616244A true US3616244A (en) | 1971-10-26 |
Family
ID=25085309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US769395A Expired - Lifetime US3616244A (en) | 1968-10-21 | 1968-10-21 | Production of lincomycin sulfoxide |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3616244A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4091204A (en) * | 1974-12-20 | 1978-05-23 | The Upjohn Company | Process for recovering lincomycin from fermentation beer |
| EP0686160A4 (en) * | 1993-02-23 | 2003-03-12 | Univ Princeton | SOLID PHASE SOLID FORMATION OF GLYCOSIDE LINKS |
| WO2006055869A3 (en) * | 2004-11-19 | 2007-04-19 | Aventis Pharma Inc | Antibiotic compounds, compositions and medical uses |
-
1968
- 1968-10-21 US US769395A patent/US3616244A/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4091204A (en) * | 1974-12-20 | 1978-05-23 | The Upjohn Company | Process for recovering lincomycin from fermentation beer |
| EP0686160A4 (en) * | 1993-02-23 | 2003-03-12 | Univ Princeton | SOLID PHASE SOLID FORMATION OF GLYCOSIDE LINKS |
| WO2006055869A3 (en) * | 2004-11-19 | 2007-04-19 | Aventis Pharma Inc | Antibiotic compounds, compositions and medical uses |
| US20080033031A1 (en) * | 2004-11-19 | 2008-02-07 | Aventis Pharmaceuticals Inc. | Antibiotic compounds, compositions and methods of treatment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5563054A (en) | Process for preparation of benzo[B]thiophene glucuronides | |
| US2928844A (en) | Celesticetin, its salts and method of preparation | |
| US3616244A (en) | Production of lincomycin sulfoxide | |
| US4554162A (en) | CL-1724 Antibiotic compounds, their production and use | |
| US3294646A (en) | Microbiological hydroxylation of norsteroids using aspergillus ochraceus | |
| US3616208A (en) | Fermentation process for 9-(beta-d-arabinofuranosyl)adenine | |
| US3816619A (en) | Ladakamycin and process for preparing same | |
| US3616237A (en) | Method of preparing thiogriseofulvins | |
| US3013947A (en) | Antibiotic production | |
| US3991052A (en) | Antibiotic A-30641 | |
| US3923602A (en) | Composition of matter and process | |
| CA1135641A (en) | A-40104 antibiotics and process for production thereof | |
| US3100176A (en) | Hygromycin and method of producing same | |
| US4335108A (en) | Paulomycin A and B and preparation thereof | |
| US4007090A (en) | Novel fermentation process for the preparation of Sulfomycin | |
| US3998698A (en) | Process for producing antibiotic U-51,640 | |
| US3023204A (en) | Viridogrisein, and its fermentative production with griseoviridin | |
| US3564019A (en) | Tetracyclic lactone antifungal agents | |
| US3718651A (en) | 3,6-bis(5-chloro-2-piperidinyl)-2,5-piperazine-dione | |
| US3833723A (en) | Alamethicin and production therefor | |
| US4230692A (en) | Ravidomycin and process of preparation | |
| EP0064409B1 (en) | Process for preparing narasin | |
| US3901880A (en) | (s)-alanyl-3-(+60 -(s)-chloro-3-(s)-hydroxy-2-oxo-azetidinylmethyl)-(s)-alanine | |
| US3183156A (en) | Antibiotic canarius and method of production | |
| US3639214A (en) | Production of 6-demethyltetracycline |